Mainz Biomed B.V.

The momentum for this stock is not very good. Mainz Biomed B.V. is not very popular among insiders. Tradey thinks it is not wise to invest in Mainz Biomed B.V..
Log in to see more information.
MYNZ Fundamental Data by TradingView

News

Mainz Biomed expands collaboration with Liquid Biosciences
Mainz Biomed expands collaboration with Liquid Biosciences

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Globe Newswire PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed's Research and Development Pipeline Promising Results of First AnalysisBERKELEY, Calif. and MAINZ, Germany, Sept...\n more…

Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago. These figures...\n more…

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research Fortress Biotech (FBIO) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $3.60 per share a year ago. These figures...\n more…

Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates

Zacks Investment Research Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. These figures...\n more…

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago. These...\n more…